Knowledge of undisclosed corporate authorship ("ghostwriting") reduces the perceived credibility of antidepressant research: A randomized vignette study with experienced nurses

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Lacasse, Jeffrey R ^a   Leo, Jonathan ^b   Cimino, Andrea N ^a   Bean, Kristen F ^a   Del Colle, Melissa ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b Lincoln Memorial University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICAL RESEARCH; MIDDLE AGED; NURSE; RANDOMIZED CONTROLLED TRIAL; WRITING;

ADULT; ANTIDEPRESSIVE AGENTS; AUTHORSHIP; BIOMEDICAL RESEARCH; FEMALE; HUMANS; MALE; MIDDLE AGED; NURSES;

EID: 84865629162     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-490     Document Type: Article

References (39)

1. Reporting bias in medical research-a narrative review. McGauran N, Wieseler B, Kreis J, Schüler Y-B, Kölsch H, Kaiser T, Trials 2010 11 1 37 10.1186/1745-6215-11-37 20388211
2. Investigator experiences with financial conflicts of interest in clinical trials. Rochon PA, Sekeres M, Hoey J, Lexchin J, Ferris LE, Moher D, et al. Trials. BioMed Central Ltd 2011 12 1 9
3. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD, BMJ 2011 343 oct25 1 6128-d6128
4. Ghost marketing: Pharmaceutical companies and ghostwritten journal articles. Perspectives in Biology and Medicine. Moffatt B, Elliott C, Johns Hopkins Univ Press 2007 50 1 18 31
5. Ethical considerations of publication planning in the pharmaceutical industry. Fugh-Berman A, Dodgson SJ, Open Med. 2008 2 4 121 e124 21602956
6. Ghost Management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? Sismondo S, PLoS Med 2007 4 9 286 10.1371/journal.pmed.0040286 17896859
7. Publication ethics and the ghost management of medical publication. Sismondo S, Doucet M, Bioethics 2010 24 6 273 283 19222451
8. The haunting of medical journals: How ghostwriting sold "HRT." Fugh-Berman AJ, PLoS Med 2010 7 9 1000335 10.1371/journal.pmed.1000335 20838656
9. Why does academic medicine allow ghostwriting? A prescription for reform. Leo J, Lacasse JR, Cimino AN, Society 2011 48 371 375 10.1007/s12115-011-9455-2
10. Clinical trials and drug promotion: Selective reporting of study 329. Jureidini J, McHenry L, Mansfield P, Int J Risk Saf Med 2008 20 1 73 81
11. Interface between authorship, industry and science in the domain of therapeutics. Healy D, Cattell D, Br J Psychiatry 2003 Jul 183 22 27 10.1192/bjp.183.1.22
12. Ghostwriting at elite academic medical centers in the United States. Lacasse JR, Leo J, PLoS Med 2010 7 2 1000230 10.1371/journal.pmed.1000230 20126384
13. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. Spielmans GI, Parry PI, Bioethical Inquiry 2010 7 1 13 29 10.1007/s11673-010-9208-8
14. Guest authorship and ghostwriting in publications related to rofecoxib. Ross J, Hill K, Egilman DS, Krumholz HM, JAMA 2008 299 15 1800 1812 10.1001/jama.299.15.1800 18413874
15. Wilson D, Singer N, Ghostwriting widespread in medical journals, study says [Internet]. nytimes.com [cited 2011 Nov. 8]. Available from: http://www.nytimes.com/2009/09/11/business/11ghost.html.
16. Singer N, Ghostwriters paid by Wyeth aided Its drugs-NYTimes.com [Internet]. nytimes.com cited 2011 Nov. 8]. Available from: http://www.nytimes. com/2009/08/05/health/research/05ghost.html?pagewanted=all.
17. Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. Schroter S, Morris J, Chaudhry S, Smith R, Barratt H, BMJ 2004 328 7442 742 743 10.1136/bmj.38035. 705185.F6 14980983
18. The impact of disclosing financial ties in research and clinical care: a systematic review. Licurse A, Barber E, Joffe S, Gross C, Arch Intern Med 2010 170 8 675 682 20421551
19. Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research. Lacasse JR, Leo J, BMC Res Notes. 2011 4 1 27 10.1186/1756-0500-4-27 21281504
20. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Keller M, Ryan N, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. J Am Acad Child Adolesc Psychiatry 2001 40 7 762 772 10.1097/00004583-200107000-00010 11437014
21. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Faul F, Erdfelder E, Lang AG, Buchner A, Beh Res Meth 2007 39 175 191 10.3758/BF03193146
22. The use of complete-case and multiple imputation-based analyses in molecular epidemiology studies that assess interaction effects. Desai M, Esserman DA, Gammon MD, Terry MB, Epidemiologic Perspectives & Innovations 2011 8 1 5 10.1186/1742-5573-8-5 23140305
23. Sprent P, Smeeton NC, Applied nonparametric statistical methods Boca Raton, FL: Chapman & Hall 4 2007
24. Quantitative methods in psychology: A power primer. Cohen J, Psychol Bull 1992 112 1 155 159 19565683
25. Brody H, Hooked: Ethics, the medical profession, and the pharmaceutical industry Rowman & Littlefield 2006
26. Shaping the intimate: Influences on the experience of everyday nerves. Healy D, Soc Stud Sci 2004 34 2 219 245 10.1177/0306312704042620 15297997
27. Ethical and moral obligations arising from revelations of pharmaceutical company dissembling. Gottstein J, Ethic Hum Psychol Psych. 2010 12 1 22 29 10.1891/1559-4343.12.1.22
28. Clinical social work & the biomedical industrial complex. Gomory T, Wong SE, David C, Lacasse JR, J Sociol Soc Welf 2011 38 4 135 165
29. Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles. Stern S, Lemmens T, PLoS Med 2011 8 8 1001070 10.1371/journal.pmed.1001070
30. Challenging medical ghostwriting in US courts. Bosch X, Esfandiari B, McHenry L, PLoS Med 2012 9 1 1001163 10.1371/journal.pmed.1001163 22291578
31. USA Today, Kaiser Family Foundation, Harvard School of Public Health, The public on prescription drugs and pharmaceutical companies [Internet]. kff.org. [cited 2011 Nov. 8] Available from: http://www.kff.org/kaiserpolls/upload/7748. pdf.
32. Selective publication of antidepressant trials and its influence on apparent efficacy. Turner E, Matthews A, Linardatos E, Tell RA, Rosenthal R, NEJM. 2008 358 3 252 260 10.1056/NEJMsa065779 18199864
33. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Kirsch I, Deacon B, Huedo-Medina T, Scoboria A, PLoS Med 2008 5 2 45 10.1371/journal.pmed.0050045 18303940
34. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Trivedi M, Rush A, Am J Psychiatry 2006 163 28 40 10.1176/appi.ajp.163.1.28 16390886
35. Questionable advertising of psychotropic medications and disease mongering. Lacasse JR, Leo J, PLoS Med 2006 3 7 321 10.1371/journal.pmed.0030321 16848626
36. Gigerenzer G, Gray JAM, Launching the century of the patient. Better doctors, better patients, better decisions: Envisioning health care 2020 Cambridge, MA: MIT Press 2011
37. Heuristic decision making. Gigerenzer G, Gaissmaier W, Annu Rev Psychol 2011 62 1 451 482 10.1146/annurev-psych-120709-145346 21126183
38. Critical thinking skills: A comparison of doctoral and masters-level students. Onwuegbuzie AJ, Coll Stud J 35 3 477 451
39. Are we training pit bulls to review our manuscripts? Walbot V, J Biol 2009 8 3 24 10.1186/jbiol125 19291274